Nav: Home

Clinical trial to use heart-derived stem cells to restore heart tissue, function

October 12, 2016

Putnam Valley, NY. (October 12, 2016) - A multi-center team of researchers are planning a clinical trial using cardiosphere-derived cells (CDCs) (a heterogeneous cluster of proliferating cardiac cells that include mesenchymal stem cells) to regenerate the tissue and improve function of the heart in patients who have suffered heart attacks (myocardial infarction, MI).

The study will use allogeneic CDCs - cells derived from donors other than the patients. In previous pre-clinical and clinical studies, CDCs have been shown to have low immunogenicity and unlikely to result in immune rejection of the cells.

The study, a randomized, double-blind, placebo-controlled phase 1 and 2 study to determine safety, will be carried out by researchers at Cedars-Sinai Heart Institute, Minneapolis Heart Institute, Scripps Medical Center, University of California at San Diego, Duke Clinical Research Institute, Johns Hopkins Hospital, and Columbus Biometrics. The study design and rationale will be published in a future issue of Cell Transplantation and is currently freely available on-line as an unedited, early epub at: http://www.ingentaconnect.com/content/cog/ct/pre-prints/content-ct-1611_chakravarty_et_al

The team's previous studies have revealed that CDC transplantation was safe and helped improve ventricular function and reduce scar tissue.

"CDC transplantation has been shown to improve the outcome in infarcted myocardium and has an excellent safety profile," said Dr. Timothy D. Henry, Director of the Division of Cardiology, Cedars-Sinai Heart Institute. "While autologous transplantation has been shown to curtail immune responses, obtaining CDCs from the patients is not feasible as it is cost-prohibitive and is associated with many logistical complications. Use of other-donated allogeneic cells, however, allows for more efficient processing and transplantation and previous studies have shown significant improvement and tolerability in subjects without the need for immunosuppression."

Named the "ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration" (ALLSTAR) trial, the study is the first randomized, double-blind, placebo-controlled trial to determine the safety and efficacy of allogeneic CDCs for patients with MI.

The study will examine several clinical endpoints that indicate cardiac regeneration, including cardiac and clinical function, quality of life, symptom alleviation, and safety.

Based on the results of the ALLSTAR Phase 1 trial, researchers predict that infusing CDCs will result in improvement for patients with MI.

"Cultural and lifestyle factors, as well as the increasing age of the population, have culminated to make heart health a significant area of interest in medicine," said Dr. Shinn-Zong (John) Lin, Tzu Chi Hospital, Hualien City, Taiwan, and Co-Editor-in-Chief of Cell Transplantation. "Cell therapy may play an integral role in the way that heart diseases are treated. This clinical study may hold promise for future approaches for treating MI."
-end-
Contact: Timothy D. Henry, 127 S. San Vicente Blvd., Suite A3100, Los Angeles, CA 90048
Email: henryt@cshs.org
Tel: (424) 315-2699
Fax: (310) 423-3522

Citation: Chakravarty T, Makkar RR, Ascheim D, Traverse JH, Schatz R, DeMaria A, Francis GS, Povsic TJ, Smith R, Lima JA, Pogoda, JM, Marban L, Henry TD. ALLogeneic Heart STem Cells to Achieve Myocardial Regeneration (ALLSTAR) trial: Rationale & Design. Cell Transplant. Appeared or available on-line: August 18, 2016.

The Co-Editors-in-Chief for CELL TRANSPLANTATION are at the Department of Neurosurgery and Brain Repair, Morsani College of Medicine, University of South Florida, Tampa, FL, USA and the Center for Neuropsychiatry, China Medical University Hospital, TaiChung, Taiwan. Contact: Paul R. Sanberg at psanberg@health.usf.edu, Shinn-Zong Lin at shinnzong@yahoo.com.tw, or Associate Editor Samantha Portis at celltransplantation@gmail.com

Cell Transplantation Center of Excellence for Aging and Brain Repair

Related Myocardial Infarction Articles:

Exercise associated with improved heart attack survival
Exercise is associated with improved survival after a heart attack, according to research published today in the European Journal of Preventive Cardiology.
Preventing mortality after myocardial infarction
How much blood to give to anemic patients after a heart attack?
Follow-up by trained nurses helps myocardial infarction patients
The quality of life of elderly myocardial infarction patients can be significantly improved without extra costs by means of so-called case management following hospitalization.
Myocardial inflammation elevated in RA patients
Two new studies measure the prevalence of myocardial inflammation in RA patients without known cardiovascular disease, assess how it is associated with high disease activity and show how disease-modifying therapy may decrease this type of inflammation, according to new research findings presented this week at the 2016 ACR/ARHP Annual Meeting in Washington.
Higher education associated with reduced heart failure risk after myocardial infarction
Higher education is associated with a reduced risk of developing heart failure after a heart attack, reports a study in more than 70,000 patients published today in the European Journal of Preventive Cardiology.
Ticagrelor for prevention after myocardial infarction: Indication of minor added benefit
In high risk of developing atherothrombotic events, ticagrelor in combination with low-dose acetylsalicylic acid is now also approved if the infarction occurred more than a year ago.
Your blood can reveal your risk for heart disease
Traditional risk factors only explain a modest proportion of cardiac incidence.
Myocardial infarction: Rush-hour for neutrophils
Researchers at Ludwig-Maximilians-Universitaet (LMU) in Munich have shown that circadian oscillations in the influx of immune cells into the damaged tissue play a crucial role in exacerbating the effects of an acute heart attack in the early morning hours.
1 in 4 patients develop heart failure within 4 years of first heart attack
One in four patients develop heart failure within four years of a first heart attack, according to a study in nearly 25,000 patients presented today at Heart Failure 2016 and the 3rd World Congress on Acute Heart Failure by Dr.
Myocardial fibrosis identified as new therapeutic target
Myocardial fibrosis could be a future therapeutic target after researchers found it correlated with adverse cardiovascular outcomes in patients with obstructive sleep apnoea referred for cardiac magnetic resonance.

Related Myocardial Infarction Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Anthropomorphic
Do animals grieve? Do they have language or consciousness? For a long time, scientists resisted the urge to look for human qualities in animals. This hour, TED speakers explore how that is changing. Guests include biological anthropologist Barbara King, dolphin researcher Denise Herzing, primatologist Frans de Waal, and ecologist Carl Safina.
Now Playing: Science for the People

#SB2 2019 Science Birthday Minisode: Mary Golda Ross
Our second annual Science Birthday is here, and this year we celebrate the wonderful Mary Golda Ross, born 9 August 1908. She died in 2008 at age 99, but left a lasting mark on the science of rocketry and space exploration as an early woman in engineering, and one of the first Native Americans in engineering. Join Rachelle and Bethany for this very special birthday minisode celebrating Mary and her achievements. Thanks to our Patreons who make this show possible! Read more about Mary G. Ross: Interview with Mary Ross on Lash Publications International, by Laurel Sheppard Meet Mary Golda...